Unfortunately, as reviewed by Kapoor et al [20], some COX-2 inhibitors (rofecoxib, valdecoxib) had to be withdrawn from the market due to serious side effects, including myocardial infarction and stroke. The gene discussed is PTGS2; the disease is myocardial infarction.